{"id":41009,"date":"2020-03-16T14:04:00","date_gmt":"2020-03-16T14:04:00","guid":{"rendered":"https:\/\/new.igihe.com\/covd19-vaccine-trial-begins\/"},"modified":"2020-03-19T10:15:01","modified_gmt":"2020-03-19T10:15:01","slug":"covd19-vaccine-trial-begins","status":"publish","type":"post","link":"https:\/\/new.igihe.com\/english\/covd19-vaccine-trial-begins\/","title":{"rendered":"COVD19 vaccine trial begins"},"content":{"rendered":"<p>Germany has closed its borders with five neighbors as European infections mount, the U.S. is moving closer to a nationwide shutdown and the Philippine island of Luzon is under strict quarantine. <\/p>\n<p>Meanwhile, the U.K. is seeing a backlash for what critics say is a dangerously slow response.<\/p>\n<p>{{What about a vaccine? }} <\/p>\n<p>While companies and researchers around the world are racing to develop one, as well as treatments, a Massachusetts biotech firm is launching human immunization trials today in Seattle.<\/p>\n<figure class=\"spip-document spip-document-35229 aligncenter\"><img decoding=\"async\" src=\"https:\/\/en-images.igihe.com\/jpg\/8ae33c1a-cc82-4936-befa-cfa404a9a1c6-large16x9_ap20058793356405.jpg\" alt=\"COVD19 vaccine trial begins\" \/><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>As coronavirus infections elsewhere topped 87,000, surpassing China\u2019s 80,860 cases, governments are taking different approaches to slowing its spread. <\/p>\n","protected":false},"author":8,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[75],"byline":[170],"hashtag":[],"class_list":["post-41009","post","type-post","status-publish","format-standard","hentry","category-news","tag-homenews","byline-igihe"],"bylines":[{"id":170,"name":"IGIHE","slug":"igihe","description":"","image":{"id":0,"url":"https:\/\/secure.gravatar.com\/avatar\/?s=96&d=mm&f=y&r=g","alt":"Default avatar","title":"Default avatar","caption":"","mime_type":"image\/jpeg","sizes":[]},"user_id":8}],"contributors":[{"id":170,"name":"IGIHE","slug":"igihe","description":"","image":{"id":0,"url":"https:\/\/secure.gravatar.com\/avatar\/?s=96&d=mm&f=y&r=g","alt":"Default avatar","title":"Default avatar","caption":"","mime_type":"image\/jpeg","sizes":[]},"user_id":8}],"featured_image":null,"_links":{"self":[{"href":"https:\/\/new.igihe.com\/english\/wp-json\/wp\/v2\/posts\/41009","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/new.igihe.com\/english\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/new.igihe.com\/english\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/new.igihe.com\/english\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/new.igihe.com\/english\/wp-json\/wp\/v2\/comments?post=41009"}],"version-history":[{"count":0,"href":"https:\/\/new.igihe.com\/english\/wp-json\/wp\/v2\/posts\/41009\/revisions"}],"wp:attachment":[{"href":"https:\/\/new.igihe.com\/english\/wp-json\/wp\/v2\/media?parent=41009"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/new.igihe.com\/english\/wp-json\/wp\/v2\/categories?post=41009"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/new.igihe.com\/english\/wp-json\/wp\/v2\/tags?post=41009"},{"taxonomy":"byline","embeddable":true,"href":"https:\/\/new.igihe.com\/english\/wp-json\/wp\/v2\/byline?post=41009"},{"taxonomy":"hashtag","embeddable":true,"href":"https:\/\/new.igihe.com\/english\/wp-json\/wp\/v2\/hashtag?post=41009"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}